ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
22.91
+0.10 (0.44%)
At close: Jun 27, 2025, 4:00 PM
22.91
0.00 (0.00%)
After-hours: Jun 27, 2025, 5:59 PM EDT
ArriVent BioPharma Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for ArriVent BioPharma stock ranges from a low of $32 to a high of $45. The average analyst price target of $39 forecasts a 70.23% increase in the stock price over the next year.
Price Target: $39.00 (+70.23%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ArriVent BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 6 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Clear Street | Clear Street | Strong Buy Initiates $32 | Strong Buy | Initiates | $32 | +39.68% | Jun 25, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $39 → $44 | Buy | Maintains | $39 → $44 | +92.06% | Jun 24, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +96.42% | Jun 24, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +74.60% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $39 → $40 | Strong Buy | Maintains | $39 → $40 | +74.60% | May 14, 2025 |
Financial Forecast
Revenue This Year
266.63M
from 160.38M
Increased by 66.25%
Revenue Next Year
n/a
from 266.63M
EPS This Year
-3.84
from -2.56
EPS Next Year
-3.28
from -3.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.8M | 123.1M | ||
| Avg | n/a | 6.4M | 69.1M | ||
| Low | n/a | n/a | 40.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,815.0% | ||
| Avg | - | - | 974.8% | ||
| Low | - | - | 523.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.83 | -1.78 | -0.42 | ||
| Avg | -3.84 | -3.28 | -2.11 | ||
| Low | -4.41 | -4.23 | -3.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.